On September 21, WUXI XDC rose 3.51% in regular trading, trading at 79.3 HKD/share, with turnover of HKD 226 million. The gain came amid broad-based strength across the Life Sciences Tools & Services sector, with peers GENSCRIPT BIO up 6.51%, WUXI BIO up 5.76%, INSILICO up 5.10%, XTALPI up 4.11%, and WUXI APPTEC up 3.50%.

On the news front, Morgan Stanley recently maintained its Overweight rating on WUXI XDC with a target price of 85 HKD, noting that management reaffirmed its full-year revenue growth target of 40% on a constant exchange rate basis, including contributions from the BioDlink acquisition. The bank highlighted that total backlog orders reached USD 2.2 billion as of H1, up 62.2% year-over-year, while a new licensing agreement with Ona Therapeutics for its WuXiTecan-2 Payload-Linker platform is expected to further boost milestone backlog. Morgan Stanley also flagged a potential FDA on-site inspection of the Wuxi facility as early as January, which could be a key catalyst for securing more commercialization orders from multinational pharma clients.

Additionally, international asset manager Schroders PLC recently raised its stake to 5.01%, crossing the disclosure threshold, signaling continued institutional confidence in the company's medium-to-long-term value as the global ADC CRDMO leader.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)